Report : Europe Breast Cancer Screening Market Forecast to 2027 - Covid-19 Impact and Regional Analysis by Test Type (Blood Marker Test, Imaging Test, Genetic Test, Immunohistochemistry Test), End User (Hospitals, Diagnostic Centers, Cancer Institutes, Research Laboratories), and Country
Hospitals Segmentto DominateEurope Breast Cancer Screening MarketDuring 2020–2027
According to a new market research study on “EuropeBreast Cancer Screening MarketForecast to 2027 – Covid-19 Impactand Analysis – by Test Type andEndUser,”the market is projectedto reach US$ 1,586.46millionby2027 from US$ 1,231.82millionin 2019. The market is estimated to grow at a CAGR of 4.3% from 2020 to 2027.The report provides trends prevailing in the Europebreast cancer screening marketalong with the drivers and restraints pertaining to the market growth.The growth of the European breast cancer screening market is attributed to the growing initiatives for breast cancer management and risingbreast cancer cases. However, the high cost associated with breast cancer screeninghinders the market growth.
The breast cancer screening market, by end user, is segmented into hospitals, diagnostic centers, cancer institutes, and research laboratories. The hospitalssegment held the largest share of the European market in 2019. Moreover,it isanticipated to register the highest CAGR of 4.9% in the market during the forecast period. The hospitals offer advanced treatment options as a resource for patients for chronic and rare disease to treat them. Moreover, the hospitals provide extensive healthcare and medical services to the patients.
Koninklijke Philips N.V., Hologic, Inc., Becton, Dickinson and Company, Myriad Genetics, Inc., Siemens Healthcare AG, Exact Sciences Corporation, OncoCyteCorporation, POC Medical systems, DanaherCorporation, and General ElectricCompany are among the leading companies in the breast cancer screening market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in October 2019, GE Healthcare launched a product, namely, the Invenia Automated Breast Ultrasound (ABUS) 2.0 in the US. The device is FDA-approved ultrasound supplemental breast screening technology, specifically designed for detecting cancer in dense breast tissues.
Europe Breast Cancer Screening Market, By Country, 2019 (%)
The report segments the Europebreast cancer screening market as follows:
By Test Type
- Blood Marker Test
- Imaging Test
- Genetic Test
- Immunohistochemistry Test
By EndUser
- Diagnostic Centers
- Hospitals
- Research Laboratories
- Cancer Institutes
By Country
- Germany
- UK
- France
- Italy
- Spain
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com